Ligand Partner CASI Pharmaceuticals Launches EVOMELA® in China
Ligand Reports Second Quarter 2019 Financial Results
Ligand Acquires Ab Initio Biotherapeutics, an Antigen-Discovery Company
Ligand to Report Second Quarter 2019 Results on July 30th
Ligand Announces Positive Top Line Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol
Ligand and SQ Innovation Enter into Exclusive Worldwide Captisol® License and Supply Agreements for High-Concentration Furosemide Formulation
ZULRESSO™ (brexanolone) CIV, a Product for Treating Postpartum Depression Using Ligand’s Captisol® in its Formulation, Launched by Sage Therapeutics
Ligand Subsidiary Vernalis and PhoreMost Limited Announce Drug Discovery Collaboration for Novel Oncology Target
Ligand Licenses VER250840 to Cumulus Oncology
